Has Nadia Khoury, MD received payments from drug or device companies?

Yes. Drug and device makers reported $32,642 in general payments to Nadia Khoury, MD across 1,353 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nadia Khoury, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nadia Khoury, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nadia Khoury, MD

Endocrinology, Diabetes & Metabolism · Southgate, MINPI 1346446143

Payments from drug & device makers

$32,642in general payments, 2019–2025

Across 1,353 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$7K
Novo Nordisk$4K
Lilly USA, LLC$3K
Corcept Therapeutics$2K
Boehringer Ingelheim$2K
AstraZeneca$1K
plus $14K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	103	$6,532
Novo Nordisk	201	$4,223
Lilly USA, LLC	182	$3,180
Corcept Therapeutics	58	$1,740
Boehringer Ingelheim	77	$1,528
AstraZeneca(2 entities)	55	$1,308
Sanofi-aventis U.S. LLC	35	$1,271
Tandem Diabetes Care, Inc.	35	$962
Dexcom, Inc.	56	$874
Xeris Pharmaceuticals, Inc.	57	$871
AbbVie	42	$855
Bayer	35	$806
Abbott	40	$667
Antares Pharma, Inc.	34	$573
Cequr Corporation	4	$511
Amneal Pharmaceuticals LLC	28	$501
Johnson & Johnson	13	$501
Amarin Pharma, Inc.	21	$364
Merck	23	$304
Endo Pharmaceuticals Inc.	17	$288
BD	19	$284
Neurocrine Biosciences, Inc.	7	$278
Novartis	17	$275
Recordati_rare_diseases_inc.	9	$252
Insulet Corporation	14	$249
Ascendis Pharma Endocrinology Inc	6	$238
Regeneron Healthcare Solutions, Inc.	9	$208
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	9	$193
Ascensia Diabetes Care US Inc.	10	$185
Madrigal Pharmaceuticals	8	$182
Amryt Pharma Holdings Ltd	10	$181
Radius Health, Inc.	9	$180
Esperion Therapeutics, Inc.	10	$179
Mannkind Corporation	7	$144
Ultragenyx Pharmaceutical Inc.	7	$144
Verity Pharmaceuticals Inc.	7	$138
Pfizer	7	$124
Astellas Pharma US Inc	7	$121
Kowa Pharmaceuticals America, Inc.	9	$112
Shire North American Group Inc	5	$90
Halozyme Inc	4	$81
Averitas Pharma Inc.	3	$73
Embecta Corp.	4	$73
Rhythm Pharmaceuticals, Inc.	3	$66
Nevro Corp.	2	$64
Ipsen Biopharmaceuticals, Inc	3	$62
Janssen Scientific Affairs, LLC	1	$59
EUSA Pharma (US) LLC	2	$52
Zealand Pharma US, Inc.	3	$51
Medtronic	2	$45
Sequel Med Tech, LLC	2	$41
Chiesi USA, Inc.	2	$41
Nestle Healthcare Nutrition Inc.	3	$38
Tolmar, Inc.	2	$31
Alvogen Inc	2	$30
GSK	1	$28
GRT US Holding, Inc.	2	$28
Currax Pharmaceuticals LLC	2	$27
Acella Pharmaceuticals, LLC	1	$22
Kyowa Kirin, Inc.	1	$21

How this compares

$32,642 in reported general payments places this provider in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024

$196,128

Medicare patients

855

Services billed

1,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Southgate

Sleman KhourySouthgate$63K
Tobias ElseAnn Arbor$3.5M
Elif OralAnn Arbor$2.9M
Jamal HammoudFlint$2.6M
Lowell SchmeltzFarmington Hills$2.3M
George GrunbergerBloomfield Hills$1.9M
Richard AuchusAnn Arbor$1.3M
Ariel BarkanAnn Arbor$553K
Gary EdelsonFarmington Hills$503K
Michael BrennanSaint Clair Shores$433K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →